These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 16316706

  • 1. Regulatory aspects of drug approval for macular degeneration.
    Gryziewicz L.
    Adv Drug Deliv Rev; 2005 Dec 13; 57(14):2092-8. PubMed ID: 16316706
    [Abstract] [Full Text] [Related]

  • 2. Pegaptanib for wet macular degeneration.
    Fraunfelder FW.
    Drugs Today (Barc); 2005 Nov 13; 41(11):703-9. PubMed ID: 16395411
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
    Earnshaw SR, Moride Y, Rochon S.
    Clin Ther; 2007 Sep 13; 29(9):2096-106; discussion 2094-5. PubMed ID: 18035208
    [Abstract] [Full Text] [Related]

  • 6. Macugen treatment for wet age-related macular degeneration.
    Tobin KA.
    Insight; 2006 Sep 13; 31(1):11-4. PubMed ID: 16817567
    [Abstract] [Full Text] [Related]

  • 7. Promising new treatments for neovascular age-related macular degeneration.
    Michels S, Schmidt-Erfurth U, Rosenfeld PJ.
    Expert Opin Investig Drugs; 2006 Jul 13; 15(7):779-93. PubMed ID: 16787141
    [Abstract] [Full Text] [Related]

  • 8. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.
    Nguyen TT, Guymer R.
    Expert Rev Clin Pharmacol; 2015 Jul 13; 8(5):541-8. PubMed ID: 26289225
    [Abstract] [Full Text] [Related]

  • 9. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration.
    Moshfeghi AA, Puliafito CA.
    Expert Opin Investig Drugs; 2005 May 13; 14(5):671-82. PubMed ID: 15926872
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib.
    Quiram PA, Hassan TS, Williams GA.
    Retina; 2007 Sep 13; 27(7):851-6. PubMed ID: 17891008
    [Abstract] [Full Text] [Related]

  • 12. VEGF inhibitors for the treatment of neovascular age-related macular degeneration.
    Barakat MR, Kaiser PK.
    Expert Opin Investig Drugs; 2009 May 13; 18(5):637-46. PubMed ID: 19388880
    [Abstract] [Full Text] [Related]

  • 13. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H, Schiller DS.
    Clin Ther; 2006 Jan 13; 28(1):36-44. PubMed ID: 16490578
    [Abstract] [Full Text] [Related]

  • 14. Intravitreal aflibercept for neovascular age-related macular degeneration.
    Xu D, Kaiser PK.
    Immunotherapy; 2013 Feb 13; 5(2):121-30. PubMed ID: 23413903
    [Abstract] [Full Text] [Related]

  • 15. Ranibizumab: new drug. Macular degeneration: second-line use due to risks.
    Prescrire Int; 2008 Feb 13; 17(93):3-6. PubMed ID: 18354841
    [Abstract] [Full Text] [Related]

  • 16. Pegaptanib in the treatment of wet, age-related macular degeneration.
    Vinores SA.
    Int J Nanomedicine; 2006 Feb 13; 1(3):263-8. PubMed ID: 17717967
    [Abstract] [Full Text] [Related]

  • 17. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases.
    Ng EW, Adamis AP.
    Ann N Y Acad Sci; 2006 Oct 13; 1082():151-71. PubMed ID: 17145936
    [Abstract] [Full Text] [Related]

  • 18. Pegaptanib (Macugen): treating neovascular age-related macular degeneration and current role in clinical practice.
    Vavvas D, D'Amico DJ.
    Ophthalmol Clin North Am; 2006 Sep 13; 19(3):353-60. PubMed ID: 16935210
    [Abstract] [Full Text] [Related]

  • 19. [The treatment of the exsudative age-related macular degeneration with choroidal neovascular membrane, its possibilities and economical indexes].
    Karel I.
    Cesk Slov Oftalmol; 2007 Sep 13; 63(5):311-9. PubMed ID: 17915581
    [Abstract] [Full Text] [Related]

  • 20. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
    VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupDepartment of Ophthalmology, Harvard Medical School, Retina Service, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, USA. djdamico@meei.harvard.edu, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET, Guyer DR, Katz B.
    Ophthalmology; 2006 Jun 13; 113(6):992-1001.e6. PubMed ID: 16647134
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.